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Combination chemotherapy with irinotecan (CPT-11) and platinum compounds is effective for treating cervical cancer. Nedaplatin
(254-S) is a new cisplatin analogue that achieves a high response rate (53%) in patients with primary cervical cancer. We performed a
phase I–II study of combination chemotherapy with CPT-11 plus 254-S for advanced or recurrent cervical cancer. The inclusion
criteria were stage IV disease or recurrence. CPT-11 and 254-S were administered intravenously on day 1, while rhG-CSF (50mg)
was given on days 3–12. This regimen was repeated after 4 weeks. Dose escalation was carried out in tandem (CPT-11/254-S: 50/70,
50/80, and 60/80mgm
 2). A total of 27 patients (stage IV¼seven, recurrence¼20) were enrolled. The phase I study enrolled eight
patients. At dose levels 1 and 2, no dose-limiting toxicities were observed. At dose level 3, the first two patients developed DLTs.
The maximum tolerated dose of CPT-11 and 254-S was 60 and 80mgm
 2, respectively, and the recommended doses were 50 and
80mgm
 2. Grade 3/4 haematologic toxicity occurred in 67% in phase II study, but there were no grade 3 nonhaematologic toxicities
except fot nausea or lethargy. In all 27 patients, there were two complete responses (7%) and 14 Partial responses (52%), for an
overall response rate of 59% (95% confidence interval: 39–78%). Among the 12 responders with recurrent disease, the median time
to progression and median survival were 161 days (range: 61–711 days) and 415 days (range: 74–801 days). This new regimen is
promising for cervical cancer.
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Cancer of the uterine cervix is one of the most common
malignancies among women and remains the leading female
malignancy in developing countries (Thigpen et al, 1994). In 1999,
about 6500 patients developed cervical cancer in Japan (Sekiya,
2002). In the USA, approximately 13000 patients developed
cervical cancer in 2000 (Robert et al, 2001). This tumour is
usually radiosensitive and highly curable at an early stage. For
patients with stage IV disease or with recurrence after radio-
therapy, however, the prognosis is still dismal (Thigpen et al,
1995). In such patients, most of the active chemotherapy agents
achieve overall response rates of 20–35% when given as
monotherapy, with a median response duration of 3–6 months
and a survival time of 5–9 months (Thigpen et al, 1981; McGuire
et al, 1996). Many combination chemotherapy regimens have also
been explored during the last two decades. High response rates
have been obtained in some studies, but it is difficult to assess the
relative merits of the various regimens because of differences in
patient selection (Buxton et al, 1989; Papadimitriou et al, 1999).
Nedaplatin (254-S) is a new cisplatin analogue with the same
carrier ligands of ammine as cisplatin but has a different leaving
group, a five-membered ring structure in which glycolate is bound
to the platinum ion as a bidentate ligand (Figure 1). This product
has an approximately 10 times higher water solubility than
cisplatin and, unlike cisplatin, shows very limited binding to
plasma protein (Sugeno et al, 1991). The plasma concentration
profile of unbound platinum after 254-S infusion has been
reported to be similar to that of total platinum, and the protein
binding of 254-S to be lower than that of CDDP (Ota et al, 1994).
Nedaplatin has a short elimination half-life and a phamacokinetic
profile similar to that of CBDCA (Sasaki et al, 1989). Nephrotoxi-
city and gastrointestinal toxicity often limits the clinical use of
antitumour agents such as CDDP, but 254-S causes less
nephrotoxicity and gastrointestinal toxicity than CDDP, although
its haematological toxicity can be a limiting factor at high dosage,
as found with CBDCA (Kameyama et al, 1990; Ota et al, 1992;
Suzumura et al, 1989). The dose-limiting toxicity (DLT) of 254-S is
myelosuppression, especially thrombocytopenia. In the Phase II
studies, 254-S monotherapy generated a 46.3% response rate
against cervical cancer, especially 53.1% in patients with squamous
cell carcinoma (Kato et al, 1992).
Irinotecan hydrochloride (CPT-11) is a semisynthetic derivative
of camptothecin, an alkaloid contained in plants such as
Camptotheca acuminate (Nitta et al, 1987). Irinotecan inhibits
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lthe activity of DNA topoisomerase I, which is necessary for
replication of DNA. Several phase II studies have shown that CPT-
11 is active against cervical cancer, and activity of CPT-11
monotherapy against recurrent or refractory cervical cancer was
revealed in phase II studies performed by the Japan CPT-11 Study
Group (24% response rate) and the MD Anderson Cancer Center
(21% response rate) (Takeuchi et al, 1991; Verschraegen et al,
1997). However, a pilot study of CPT-11 in patients with platinum-
resistant squamous cell carcinoma failed to show any tumour
response (Ivrin et al, 1998).
Kanazawa et al (2001) reported that the combination of 254-S
and CPT-11 showed marked synergistic activity against SBC-3 and
PC-14 lung cancer cell lines. This synergistic effect was dependent
on the treatment schedule and was produced by concurrent
exposure to 254-S and CPT-11. They analysed the mechanism of
synergy and demonstrated that the topoisomerase I inhibitory
effect of CPT-11 was enhanced 10-fold in the presence of 254-S.
Based on these findings, the combination of 254-S and CPT-11 may
well be clinically useful. Machida et al (2003) performed a phase I
study of chemotherapy using CPT-11 plus 254-S for advanced or
recurrent cervical cancer. They concluded that the DLT was
neutropenia, and their recommended doses of CPT-11 (days 1, 8,
and 15) and 254-S (day 1) were 50 and 60mgm
 2, respectively.
Recombinant human granulocyte colony-stimulating factor (rhG-
CSF) can activate haematopoiesis and thus prevent chemotherapy-
induced neutropenia or accelerate recovery from this complica-
tion, allowing patients to receive full per protocol doses of
anticancer drugs. The G-CSF was expected to increase the dose
intensity of combination chemotherapy with 254-S plus CPT-11.
Accordingly, we performed a phase I–II study of CPT-11 plus
254-S with rhG-CSF support in patients with advanced or recurrent
cervical cancer.
MATERIALS AND METHODS
Patient selection
The chief eligibility criteria were as follows: (1) histologically
proven cervical cancer (stage IV or recurrent disease), (2) at least
one measurable tumour lesion documented radiographically, and
(3) an interval 44 weeks between the end of previous treatment
(including radiotherapy) and this study. Other eligibility criteria
were an age o75 years, performance status (WHO) p2 and life
expectancy 43 months. Patients were also required to meet all of
the following laboratory criteria: WBC count X3000mm
 3 or
absolute neutrophil count X1500mm
 3, platelet count
X100000mm
 3, serum transaminases p60IUml
 1, total bilir-
ubin p1.5mgdl
 1, serum creatinine p1.5mgdl
 1, and blood urea
nitrogen p20mgdl
 1. The nature and purpose of the study were
fully explained to each patient and all patients gave written
informed consent. The study was also approved by the institu-
tional review board of Osaka City General Hospital. Patients were
excluded for any of the following conditions: other cancer
(metachronous or synchronous); concurrent infection; pre-exist-
ing diarrhoea; intestinal paralysis or obstruction; interstitial
pneumonia or pulmonary fibrosis; massive ascites; pleural
effusion; uncontrolled diabetes; or a history of severe drug
hypersensitivity.
Treatment schedule
A 90-min intravenous infusion of CPT-11 (in 500ml of 0.9%
normal saline) was given on day 1, after which 254-S (in 500ml of
0.9% normal saline) was also administered intravenously over
90min. Then, patients received intravenous hydration with
1000ml of 0.9% saline or 5% dextrose. All patients were treated
with a 5-HT3 receptor antagonist before administration of the
anticancer drugs. Recombinant human granulocyte colony-stimu-
lating factor (50mg) was given on days 3–12. Before starting the
next cycle, it was confirmed that the leukocyte was X3000ml
 1, the
neutrophil count was X1500ml
 1, and the platelet count was
X100000ml
 1, with no diarrhoea, and hepatorenal function
meeting the eligibility criteria. Treatment was repeated every 4
weeks for at least two cycles, unless the disease progressed.
Treatment was, generally, also stopped if the response was defined
as no change (NC) after two cycles. The doses of the two anticancer
agents were escalated in tandem, as shown in Table 1. Recombi-
nant human granulocyte colony-stimulating factor was also
administered when grade 4 neutropenia or grade 3 neutropenia
associated with infection occurred. Additionally, if the leukocyte
count was o1000ml
 1, neutrophil count was o500ml
 1, or platelet
count was o25000ml
 1 during any cycle, the doses of CPT-11 and
254-S were reduced by one level for the next cycle. Physical
examination, complete blood count, and biochemistry tests were
carried out weekly.
Evaluation of response and toxicity
Tumour response was evaluated according to World Health
Organization (WHO) criteria (WHO, 1979). Tumours were
measured using contrast-enhanced computed tomography (CT)
after two cycles of chemotherapy and also 1 month after the end of
the treatment. Computed tomography scans were subsequently
performed every 3 months for 2 years. The response was assessed
from the product of the two largest perpendicular diameters using
the following criteria: complete response (CR) was defined as the
disappearance of all detectable lesions with no new lesions for at
least 4 weeks; partial response (PR) was defined as X50%
reduction of the sum of the products of measurable lesions for
at least 4 weeks. Progressive disease (PD) was defined as a X25%
increase in the sum of the products of all measurable lesions,
reappearance of any lesion that had disappeared, or appearance of
a new lesion. No change was defined as any outcome that did not
qualify as response or progression. Measurements were performed
by an experienced radiologist who was blinded to patient
information. Patients were considered evaluable for response if
they received at least one full cycle of per protocol therapy.
Toxicity was evaluated by the Japan Clinical Oncology Group
(JCOG) criteria (Tobina et al, 1993). Complete blood counts,
biochemistry tests, and liver function tests were performed weekly.
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Figure 1 Structure of nedaplatin.
Table 1 Dose escalation schedule
Dose level
Irinotecan
(mgm
 2)
Nedaplatin
(mgm
 2)
15 0 7 0
25 0 8 0
36 0 8 0
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lPatients were considered evaluable for toxicity if they received at
least one full cycle according to the protocol. Dose-limiting toxicity
was defined as grade 4 haematologic toxicity (a leukocyte count
o1000ml
 1, neutrophil count o500ml
 1, or platelet count
o25000ml
 1), or grades 3–4 nonhaematologic toxicity (except
for alopecia, nausea, and vomiting) or failure to recover
sufficiently to start the second cycle within 6 weeks. At least three
assessable patients were treated at each dose level. If none of these
three patients experienced DLT, then the next dose level was
started. If one patient developed DLT, the cohort was expanded to
six patients. The maximum tolerated dose (MTD) was defined as
the dose level at which at least two out of three patients or three
out of six patients experienced DLT. The recommended dose (RD)
of 254-S and CPT-11 for the subsequent phase II study was set at
one level below the MTD.
Statistical analysis
When the number of subjects required for a 95% confidence
interval (95% CI) of 720% was calculated by setting the expected
response rate as 35%, it was 22 subjects. Therefore, the target
number of subjects for this study was set as 22. Primary statistical
analysis consisted of estimation of the complete and partial
response rates. The response rate was calculated as the percentage
of complete plus partial responders relative to the total number of
assessable patients and 95% CIs for the response were computed
using the binomial distribution function.
RESULTS
Patient characteristics
A total of 27 patients were enrolled in this study between 10
January 1998 and 1 March 2003. Four patients were in stage IVA,
three patients were in stage IVB, and 20 patients had recurrent
cancer. Among those recurrent 20 patients, the duration from
primary therapy to recurrence was o1 year for 10 patients, from
X1t oo2 years for seven patients, and 42 years for three
patients. Their median age was 54 years (range: 32–67 years). In
all, 22 patients had a PS of 0, four had a PS of 1, and one had a PS
of 2. A total of 20 patients had squamous cell carcinoma, four had
adenosquamous cell carcinoma, and three had adenocarcinoma.
Seven patients had no prior therapy, two had received chemo-
radiotherapy, five had undergone surgery, and 13 had received
both surgery and chemoradiation. The chemoradiotherapy con-
sisted of radiotherapy for whole pelivis and intravenous weekly
CDDP treatment (30mgm
 2week
 1) with or without brachyther-
apy. The tumour was located in the pelvic cavity in 11 cases, lung
in nine cases, liver in five cases, paraaortic lymph nodes in four
cases, and Virchow’s node in one case. All patients were assessable
for toxicity and response. A total of 71 cycles of therapy were
administered. The clinical features of the patients are summarised
in Table 2.
Toxicity
Phase I study The phase I study enrolled eight patients. At dose
levels 1 and 2, no DLTs were observed. At dose level 1, three
patients developed grade 3 neutropenia, while one out of three
patients had grade 3 neutropenia at dose level 2. At dose level 2,
one out of three patients only received one course because of PD.
At dose level three, the first two patients developed grade 4
neutropenia and one of them had febrile neutropenia for 4 days.
Both received rhG-CSF and one of them also received intravenous
antibiotics. None of the patients experienced nonhaematologic
DLTs. In five cases, treatment could be performed every 4 weeks,
but treatment delay occurred in two cases (3 days and 7 days).
Therefore, the MTD was set as 60 and 80mgm
 2 for CPT-11 and
254-S, respectively, and the doses for the phase II study were set at
50 and 80mgm
 2. Toxicities are summarised in Tables 3 and 4.
Phase II study A total of 22 patients, including three patients
from the phase I study, were registered for the phase II study. In 7
Table 2 Characteristics of the eligible patients (n¼27)
Characteristic n
Age (years)
Median 54
Range 32–67
WHO PS
02 2
14
21
FIGO stage
IVA 4
IVB 3
Recurrent 20
Site of recurrent
Inside radiation field 5
Outside radiation field 22
Histology
Squamous cell carcinoma 20
Adenosquamous cell carcinoma 4
Adenocarcinoma 3
Prior therapy
None 7
Chemoradiation 2
Surgery 5
Surgery plus chemoradiation 13
Table 3 Haematologic toxicity
Leukopenia Neutropenia Anemia Thrombocytopenia
Dose level G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G1 G2 G3 G4 Grade 3/4 toxicity (%)
Phase I
1( n¼3) 0 0 3 0 0 1 2 0 0 1 1 1 0 0 0 100
2( n¼3) 0 2 1 0 0 2 1 0 1 1 0 0 0 0 0 33
3( n¼2) 0 0 1 1 0 0 0 2 0 0 2 0 0 1 1 100
Phase II
2 (cycles¼50)
a 6 1 91 8 1 9 92 2 61 71 71 0 4 8 4 1 6 2
a
1 (cycles¼8) 0 2 5 1 0 1 3 4 1 2 5 1 2 2 1 100
Total (cycles¼58) 6 21 23 2 9 10 25 10 18 19 15 5 10 6 2 67
aThree patients were from the phase I study.
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lof 22 patients, grade 4 neutropenia was observed and for these
seven patients, the doses of CPT-11 and 254-S were reduced by one
level for the next cycle. For phase II study, 50 cycles were
administered at dose level 2 and eight cycles were administered at
dose level 1. Finally, a total of 58 cycles were administered, with a
median of two cycles per person (range: 1–6 cycles). Haematologic
toxicities are summarised in Table 3. Grade 3 or 4 leukopenia,
grade 3 or 4 neutropenia, grade 3 anemia, and grade 3 or 4
thrombocytopenia occurred in 43% (25 out of 58), 60% (35 out of
58), 26% (15 out of 58), and 14% (8 out of 58) of all cycles,
respectively. The seven patients who had grade 4 neutropenia
recovered after short-term therapy with rhG-CSF (median: 4 days;
range: 3–9 days), and none of them developed febrile neutropenia.
The median leukocyte count nadir occurred on day 16 (range: days
12–22). No patient required transfusion, including platelets or red
blood cells. Nonhaematologoic toxicities are summarised in
Table 4. There were no severe nonhaematologic toxicities. Only
two patients received one cycle of chemotherapy because of PD.
Treatment delays occurred in 12 patients (median: 7 days; range:
3–12 days). Occurrence of toxicity, including haematologic and
nonhaematologic toxicity, did not appear to be associated with the
cumulative dose.
Response
At dose level 1, one out of three patients achieved a clinical
response, but there were no responders at dose level 3. In the phase
II study (n¼22), there were two CRs (9%) and 13 PRs (59%), for
an overall response rate of 68% (95% CI: 49–84%).
In all 27 patients, there were two CRs (7%) and 14 PRs (52%),
for an overall response rate of 59% (95% CI: 39–78%). Complete
response occurred in patients with lung and Virchow’s node
metastasis as the measurable target lesions. Nine patients had NC
(33%) and two patients had PD (7%) (Table 5). Among the 12
responders with recurrent disease, the median time to progression
and median survival were 161 days (range: 61–711 days) and 415
days (range: 74–801 days). In one CR case, recurrence occurred at
534 days and the patient is now alive with disease at 801 days.
Another CR case is now alive without disease at 711 days. In all, 27
cases, the median survival was 394 days (61–801 days).
Table 6 shows the responses stratified according to various
clinical factors in all cases. The response rate was 57% (4 out of 7)
and 60% (12 out of 20) for primary and recurrent cancer,
respectively. The response rate was 53% (8 out of 15) and 67% (8
out of 12) for patients with and without prior treatment except for
surgery, respectively. Among 22 patients with diseases outside the
radiation field, 14 (two CRs and 12 PRs) achieved a clinical
response (64%). Among five patients with disease inside the
radiation field, two achieved a clinical response (PR: 40%). In the
10 patients less than 50 years old, the response rate was 80%, while
it was 47% in the 17 patients more than 50 years old. After
chemotherapy, three out of four stage IVA patients received
surgery plus chemoradiation and one received chemoradiation
alone, and two out of three stage IVB patients received
chemoradiotherapy and one received radiotherapy. Among the
remaining 20 recurrent patients, one patient received chemoradia-
tion, two patients received radiotherapy, and two had further
chemotherapy after CPT-11 plus 254-S. When the response of
measurable lesions was analysed, it was seven of 11 (64%) at the
primary site, four of nine (44%) for lung, three of five (60%) for
liver, and four of five (80%) for lymph nodes.
DISCUSSION
We conducted a phase I–II study of combination chemotherapy
with CPT-11 plus 254-S and rhG-CSF support for advanced or
recurrent cervical cancer. At dose level 3 (CPT-11/254-S: 60/
80mgm
 2), the first two patients developed grade 4 neutropenia
and one of them had febrile neutropenia for 4 days. Accordingly,
we defined the MTD for CPT-11/254-S as 60/80mgm
 2 and the RD
for the phase II study as 50/80mgm
 2. In the phase II study
(n¼22), 73% of the 22 patients experienced grade 3 or 4
neutropenia, although the seven patients who had grade 4
neutropenia recovered with rhG-CSF support and a good clinical
response rate (68%) was achieved. Grade 3 or 4 neutropenia
occurred in 60% (35 out of 58) of all cycles in phase II study,
respectively. In all 27 patients, there were two CRs (7%) and 14 PRs
(52%), for an overall response rate of 59% (95% CI: 39–78%).
Machida et al (2003) conducted a phase I study of this therapy
for advanced or recurrent cervical cancer and concluded that (1)
the DLT was neutropenia, 2) the MTD of CPT-11 (days 1, 8, and
15)/254-S (day 1) was 60/60mgm
 2, and (3) the RD was 50/
60mgm
 2. Their data are concordant with ours. However,
Oshita et al (2003) performed a phase I–II study in patients with
Table 4 Nonhaematologic toxicity
Nausea Diarrhoea Haematouria Hepatotoxicity alopecia mucocitis lethargy
Dose level G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G1 G2 G3 G4 G1 G2 G3 G4
Phase I
1( n¼3 ) 21 00 1 0000000 10 0 0 2 10000 2 100
2( n¼3 ) 30 00 1 0000000 00 0 0 2 11000 3 000
3( n¼2 ) 10 10 0 1000100 00 0 0 1 11000 0 110
Phase II
2 (cycles¼50)
a 3 0 1 2 40 1 2 70050001 20 0 0 1 7 85000 2 4 700
1 (cycles¼8 ) 62 00 3 0001000 10 0 0 2 31000 8 000
Total (cycles¼5 8 ) 3 6 1 4 40 1 5 70060001 30 0 0 1 91 16000 3 2 700
aThree patients were from the phase I study.
Table 5 Outcome of treatment
Response
Dose level CR PR NC PD Total
1( n¼3) 0 1 2 0 1/3
2( n¼22) 2 13 5 2 15/22
3( n¼2) 0 0 2 0 0/2
Total (n¼27) 2 14 9 2 16/27
CR¼Complete response; PR¼Partial response; NC¼No change; PD¼
Progressive disease.
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lnon-small-cell lung cancer and could not find the MTD, while the
RD of CPT-11 (days 1 and 8)/254-S was 60/100mgm
 2. Their data
are somewhat surprising, because a previous study set the RD for
254-S monotherapy at 100mgm
 2 (Ota et al, 1992). In Oshita’s
study, 90% of the patients (38 out of 42) had not received prior
therapy and 64% (27 out of 42) of the patients were male. In our
study and that of Machida, however, 74 and 58% of the patients
had received prior therapy and all of the patients were female, so
such differences may explain the different results, but further
investigation is required.
In previous studies of combination chemotherapy with CPT-11
plus 254-S, CPT-11 was given on days 1 and 8, but we only gave
CPT-11 on day 1 in this study for the following reasons: (1) The
combination of 254-S and CPT-11 was reported to show marked
synergy in SBC-3 and PC-14 lung cancer cell lines (Kanazawa et al,
2001), with the synergistic effect being dependent on the treatment
schedule and being produced by concurrent exposure to 254-S and
CPT-11. They analysed the mechanism of this synergistic effect
and demonstrated that the inhibition of topoisomerase I by CPT-
11 was enhanced 10-fold in the presence of 254-S. (2) At present,
platinum compounds are thought of as key drugs for cervical
cancer, so we focused more on the platinum compound in this
study based on these findings.
In patients with advanced or recurrent cervical cancer, most
active single agents achieve overall response rates of 15–35%
(Thigpen et al, 1981; Bonomi et al, 1985; Takeuchi et al, 1991;
McGuire et al, 1996; Verschraegen et al, 1997; Ivrin et al, 1998;
Morris et al, 1998).
Several combination chemotherapy regimens that contain
cisplatin have been tested in phase II studies, and objective
responses have been documented in 30–70% of the patients, while
the median overall survival time ranged between 7 and 12 months
(Buxton et al, 1989; Murad et al, 1994; Long et al, 1995;
Papadimitriou et al, 1997, 1999; Rose et al, 1999). Although it is
difficult to directly compare the relative merits of the combined
regimens with the single agents, combination chemotherapy seems
to be superior to single-agent therapy based on these phase II
studies. A randomised study performed by the GOG in 438
assessable patients indicated that the combination of cisplatin and
ifosfamide achieved a higher response rate and a longer
progression-free survival time compared with cisplatin alone.
However, the combination was more toxic and there was no
difference of overall survival (Omura et al, 1997), suggesting the
need to develop new combinations for advanced or recurrent
cervical cancer. In this study, the overall response rate was 59%,
while among the 12 responders with recurrent disease, the median
time to progression and median survival time were 161 days
(range: 61–711 days) and 415 days (range: 74–801 days),
respectively. Thus, the regimen seems to be promising for treating
advanced or recurrent cervical cancer.
Brader et al (1998) reported that the site of recurrence (inside
the radiation field or outside it) and the age of the patient could
predict the response to chemotherapy for cervical cancer. In
addition, adenocarcinoma is thought to be more resistant to
chemotherapy compared with squamous cell carcinoma. In the
present study, both squamous cell carcinoma and adenocarcinoma
were sensitive to the combination of CPT-11 plus 254-S. However,
this regimen tend to be more effective for disease recurring outside
the radiation field than for recurrence inside the radiation field
(RR; 64 vs 40%). In addition, this regimen tend to be more effective
for young patients.
In conclusion, the RD of CPT-11/254-S with rhG-CSF was 50/
80mgm
 2, and this regimen seems to be promising for treating
advanced or recurrent cervical cancer.
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